Nothing Special   »   [go: up one dir, main page]

TNSN98141A1 - Derives 1,2,3, 4-tetrahydronapthalene substitues - Google Patents

Derives 1,2,3, 4-tetrahydronapthalene substitues

Info

Publication number
TNSN98141A1
TNSN98141A1 TNTNSN98141A TNSN98141A TNSN98141A1 TN SN98141 A1 TNSN98141 A1 TN SN98141A1 TN TNSN98141 A TNTNSN98141 A TN TNSN98141A TN SN98141 A TNSN98141 A TN SN98141A TN SN98141 A1 TNSN98141 A1 TN SN98141A1
Authority
TN
Tunisia
Prior art keywords
alkyle
cycloalkyle
heteroatomes
alkoxy
aryl
Prior art date
Application number
TNTNSN98141A
Other languages
English (en)
Inventor
Mats Linderberg
Svante Ross
Seth-Olov Thorberg
Stefan Berg
Bengt Ulff
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN98141A1 publication Critical patent/TNSN98141A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENTION SE RAPPORTE A DE NOUVEAUX DERIVES PIPERIDYLE-OU PIERPAZINYLE-1,2,3,4-TETRAHYTDRONAPHTALENE SUBSTITUES AYANT LA FORMULE I , OU X EST N OU CH ; Y EST NR2CH2, CH2-NR2,NR2-CO, CO-NR2 OU NR2SO2 OU R2 EST H OU C1-C6 ALKYLE ; R1 EST H, C1-C6 ALKYLE OU C3-C6 CYCLOALKYLE ; R3 EST C1-C6 ALKYLE, C3-C6 CYCLOALKYLE OU (CH2)n - ARYLE, OU ARYLE EST PHENYLE OU UN NOYAU HETEROAROMATIQUE CONTENANT UN OU DEUX HETEROATOMES SELECTIONNES A PARTIR DE N, O ET S ET QUI PEUVENT ETRE MONO OU DISUBSTITUES, n EST O-4 ; R9 EST C1-C6 ALKYLE, C3-C6 CYCLOALKYLE, OCF3, OCHF2, OCH2F, HALOGENE, CN, CF3, OH, C1-C6 ALKOXY, C1-C6 ALKOXY-C1-C6 ALKYLE, NR6R7,SO3CH3, SO3CF3, SO2NR6R7, UN NOYAU HETEROCYCLIQUE OU HETEROAROMATIQUE NON SUBSTITUE OU SUBSTITUE CONTENANT UN OU DEUX HETEROATOMES SELECTIONNES PARMI N ET O, ET OU LES OU LES SUBTITUANTS SONT C1-C6 ALKYLE, OU COR8, OU R6, R7 ET R8 SONT TELS QUE DEFINIS PLUS HAUT, COMME ENANTIOMERES (R), ENANTIOMERES (S) OU RACEMATES SOUS LA FORME D'UNE BASE LIBRE OU DE SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELLE-CI, UN PROCEDE EN VUE DE LEUR PREPARATION, DES COMPOSITIONS CONTENANT LES DITS COMPOSES THERAPEUTIQUEMENT ACTIFS, ET L'EMLOI DES DITS COMPOSES ACTIFS EN THERAPIE.
TNTNSN98141A 1997-07-25 1998-07-23 Derives 1,2,3, 4-tetrahydronapthalene substitues TNSN98141A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds

Publications (1)

Publication Number Publication Date
TNSN98141A1 true TNSN98141A1 (fr) 2005-03-15

Family

ID=20407828

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98141A TNSN98141A1 (fr) 1997-07-25 1998-07-23 Derives 1,2,3, 4-tetrahydronapthalene substitues

Country Status (37)

Country Link
US (3) US6313118B1 (fr)
EP (1) EP1000048B1 (fr)
JP (1) JP3895923B2 (fr)
KR (1) KR20010022171A (fr)
CN (1) CN1270585A (fr)
AR (2) AR013370A1 (fr)
AT (1) ATE228510T1 (fr)
AU (1) AU739569B2 (fr)
BR (1) BR9811042A (fr)
CA (1) CA2296518A1 (fr)
DE (1) DE69809755T2 (fr)
DK (1) DK1000048T3 (fr)
DZ (1) DZ2569A1 (fr)
EE (1) EE04238B1 (fr)
ES (1) ES2187983T3 (fr)
HK (1) HK1025963A1 (fr)
HR (1) HRP980404B1 (fr)
HU (1) HUP0004334A3 (fr)
ID (1) ID24583A (fr)
IL (1) IL134108A0 (fr)
IS (1) IS5358A (fr)
MA (1) MA26521A1 (fr)
NO (1) NO315609B1 (fr)
NZ (1) NZ502384A (fr)
PL (1) PL338563A1 (fr)
PT (1) PT1000048E (fr)
RU (1) RU2194696C2 (fr)
SE (1) SE9702799D0 (fr)
SI (1) SI1000048T1 (fr)
SK (1) SK283918B6 (fr)
TN (1) TNSN98141A1 (fr)
TR (1) TR200000229T2 (fr)
TW (1) TW438781B (fr)
UA (1) UA69389C2 (fr)
WO (1) WO1999005134A1 (fr)
YU (1) YU2300A (fr)
ZA (1) ZA986588B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
SE0102856D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab A new method
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
CA2566934A1 (fr) * 2004-05-21 2005-12-01 Pfizer Products Inc. Tetrahydronaphthylpiper- azines utilisees en tant qu'agonistes inverses, agonistes partiels et antagonistes de 5-ht1b
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008130321A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 807
WO2008130323A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 8-pipérazine-tétrahydronaphtalène utilisés pour le traitement de la douleur
WO2008130319A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 805
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130322A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 5-hétérocyclyl-chromane utilisés pour le traitement de la douleur
EP2098511A1 (fr) 2008-03-07 2009-09-09 Solvias AG Procédé pour la préparation de composés contenant une structure d'hydronaphtalène avec un cycle benzène à substitution asymétrique
MY157518A (en) 2008-06-20 2016-06-15 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CN105324372B (zh) 2013-06-21 2018-03-06 武田药品工业株式会社 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919624A1 (de) 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0533268B1 (fr) 1991-09-18 2001-08-16 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
EP0689536B1 (fr) 1993-03-16 2001-05-23 Pfizer Inc. Derives de naphtalene
WO1995011243A1 (fr) 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
SE9702799D0 (sv) 1997-07-25
TW438781B (en) 2001-06-07
NZ502384A (en) 2001-05-25
HUP0004334A3 (en) 2002-10-28
US6534652B2 (en) 2003-03-18
CA2296518A1 (fr) 1999-02-04
WO1999005134A1 (fr) 1999-02-04
KR20010022171A (ko) 2001-03-15
IL134108A0 (en) 2001-04-30
EP1000048A1 (fr) 2000-05-17
ID24583A (id) 2000-07-27
NO315609B1 (no) 2003-09-29
HRP980404A2 (en) 1999-04-30
SK188399A3 (en) 2000-07-11
HRP980404B1 (en) 2002-10-31
ATE228510T1 (de) 2002-12-15
CN1270585A (zh) 2000-10-18
JP2001510837A (ja) 2001-08-07
BR9811042A (pt) 2000-08-15
JP3895923B2 (ja) 2007-03-22
NO20000356L (no) 2000-03-27
YU2300A (sh) 2002-10-18
PL338563A1 (en) 2000-11-06
RU2194696C2 (ru) 2002-12-20
AR046193A2 (es) 2005-11-30
MA26521A1 (fr) 2004-12-20
HUP0004334A2 (en) 2001-03-28
ES2187983T3 (es) 2003-06-16
TR200000229T2 (tr) 2000-06-21
PT1000048E (pt) 2003-03-31
ZA986588B (en) 1999-01-25
AR013370A1 (es) 2000-12-27
DZ2569A1 (fr) 2003-02-15
HK1025963A1 (en) 2000-12-01
EP1000048B1 (fr) 2002-11-27
NO20000356D0 (no) 2000-01-24
UA69389C2 (uk) 2004-09-15
SK283918B6 (sk) 2004-05-04
EE04238B1 (et) 2004-02-16
US20010051626A1 (en) 2001-12-13
EE200000041A (et) 2000-10-16
US6410532B2 (en) 2002-06-25
IS5358A (is) 2000-01-24
DK1000048T3 (da) 2003-03-03
DE69809755T2 (de) 2003-07-17
DE69809755D1 (de) 2003-01-09
SI1000048T1 (en) 2003-04-30
AU8370398A (en) 1999-02-16
AU739569B2 (en) 2001-10-18
US20010051623A1 (en) 2001-12-13
US6313118B1 (en) 2001-11-06

Similar Documents

Publication Publication Date Title
TNSN98141A1 (fr) Derives 1,2,3, 4-tetrahydronapthalene substitues
MX9806255A (es) Piperazinas aromaticas novedosas derivadas de cicloazanos sustituidos, metodo para preparar las mismas, composiciones farmaceuticas y uso de las mismas como farmacos.
OA09482A (fr) "Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
SE8201854L (sv) N-substituerade amino-aminosyror
ATE22889T1 (de) 8-chlor-1,5-benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
IL123583A (en) 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them
ZA929815B (en) New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing these compounds
AU6747687A (en) New derivatives of decahydroquinoline,their preparation process, the preparation intermediates, their use as medicaments and the compositions containing them
BG103207A (en) Esters of the arylcycloalkanecarboxylic acids, their application, pharmaceutical compositions and their preparation
KR950701904A (ko) 치환된(아릴알콕시벤질)아미노프로판아미드 유도체, 이의 제조방법 및 항간질제, 신경보호제 및 항우울증제로서의 이의 용도[Substituted(arylalkoxybenzyl) aminopropanamide derivatives, their preparation and use as anti-epileptic neuroprotective and antidepressant agents]
BG103426A (en) Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases
KR940003953A (ko) 1. 4-벤조디옥산 유도체
IL112432A0 (en) Fatty acid derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
DE69028342D1 (de) Cephalosporinverbindungen und Verfahren zu ihrer Herstellung
LV10235A (lv) Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode
FI78905B (fi) Foerfarande foer framstaellning av farmakologiskt aktiva n-/(1-etyl-2-pyrrolidinyl)metyl/bensamidderivat.
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
EA200000657A1 (ru) Производные замещенного изохинолина и их использование в качестве антиконвульсивных средств
ES550744A0 (es) Un metodo para preparar un derivado de urea sustituido con aminoalquilo
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
ZA200200009B (en) Novel fluorinated benzodioxane imidazoline derivatives, their preparation and their therapeutic applications.
HUP0000783A2 (hu) N-(piridinil-amino)-izoindolinok és származékaik, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2000008006A3 (fr) Composes pharmaceutiques
ES2027492A6 (es) Procedimiento de preparacion de nuevos derivados dihidropirimidotiazinos y de sus sales de adicion acidas farmaceuticamente aceptables.